

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-3 (original): canceled.

Claim 4 (new): A method of inhibiting neovascularization in a mammalian eye, comprising administering to the mammal in need thereof a composition comprising an amount of squalamine or a pharmaceutically acceptable salt thereof effective to inhibit the neovascularization.

Claim 5 (new): The method of claim 4, wherein the effective amount is about 0.1 to about 10 mg/kg body weight.

Claim 6 (new): The method of claim 4, wherein the neovascularization is associated with macular degeneration.

Claim 7 (new): The method of claim 6, wherein the composition is administered intravenously or subcutaneously.

Claim 8 (new): The method of claim 6, wherein the composition is administered topically.

Claim 9 (new): The method of claim 4, wherein the composition is used in combination with at least one other therapy for inhibiting neovascularization in a mammalian eye.

Claim 10 (new): The method of claim 6, wherein the composition is used in combination with at least one other therapy for treating macular degeneration in a mammal.

Claim 11 (new): A method of treating macular degeneration in a mammal, comprising administering to the mammal a composition comprising an amount of squalamine or a pharmaceutically acceptable salt thereof effective to treat the macular degeneration.

Claim 12 (new): The method of claim 11, wherein the effective amount is about 0.1 to about 10 mg/kg body weight.

Claim 13 (new): The method of claim 11, wherein the macular degeneration is age-related macular degeneration.

Claim 14 (new): The method of claim 13, wherein the age-related macular degeneration is the wet form.

Claim 15 (new): The method of claim 13, wherein the age-related macular degeneration is the dry form.

Claim 16 (new): The method of claim 4 or claim 11, wherein the mammal is a human.

Claim 17 (new): The method of claim 11, wherein the composition is administered intravenously.

Claim 18 (new): A method of treating macular degeneration in a human, comprising administering systemically to the human in need of treatment, a composition comprising an amount of squalamine or a pharmaceutically acceptable salt thereof effective to treat the macular degeneration.

Claim 19 (new): The method of claim 18, wherein the systemic administration is selected from the group consisting of intravenous, subcutaneous and intramuscular injection.

Claim 20 (new): The method of claim 18, wherein the method consists essentially of administering to the human in need of treatment, a composition comprising an amount of squalamine or a pharmaceutically acceptable salt thereof effective to treat the macular degeneration.

Claim 21 (new): The method of claim 18, wherein the method consists of administering to the human in need of treatment, a composition comprising an amount of squalamine or a pharmaceutically acceptable salt thereof effective to treat the macular degeneration.

Claim 22 (new): The method of any one of claims 4, 11 or 18 wherein the composition consists essentially of squalamine.

Claim 23 (new): The method of any one of claims 4, 11 or 18 wherein the composition consists of squalamine.

Claim 24 (new): The method of any one of claims 4, 11 or 18 wherein the composition further comprises one or more pharmaceutically acceptable excipients.